Tango Therapeutics, Inc. 4

Director Lesley Ann Calhoun received 4,000 RSU-based common shares and a stock option for 25,000 shares of Tango Therapeutics, Inc. at a $20.22 exercise price as part of a routine equity award.

On June 5, 2026, Tango Therapeutics, Inc. director Lesley Ann Calhoun received an equity compensation package consisting of 4,000 shares of common stock in the form of restricted stock units that will vest in full on the earlier of June 5, 2027 or the next annual stockholders’ meeting, and a stock option grant for 25,000 shares at an exercise price of $20.22 per share vesting in 12 equal monthly installments starting July 5, 2026, all subject to continued service. Following these awards, Calhoun beneficially owns 16,500 shares of common stock and an option to purchase 25,000 additional shares, representing a routine director compensation grant rather than an open-market purchase or sale. The estimated grant-date value of the RSUs is approximately $80,880 based on the $20.22 reference price, with the option providing additional upside leverage tied to future stock performance.

Filing Facts

CIK

1819133

Ticker

TNGX

Form

4

Source Type

sec

Accession

0001193125-26-262205

Alert Tier

5